Chronic obstructive pulmonary disease with frequent exacerbations
LWR-620 against placebo to reduce exacerbations in COPD. Sponsor: Litware Respiratory (fictional), Respiratory.
Every risk that applies to this study, scored after TransCelerate's risk assessment tool. The KRIs and QTLs tabs set out what watches each one.
This study carries 27 risks
They come from its protocol answers, its countries and the kinds of site it uses: four score high and nine medium. Of those, nine are not yet watched by any KRI, KPI or QTL. A new KRI or a closer look there would lower the risk most.
| Score | Risk | Why it applies here | L×I×D | Watched by |
|---|---|---|---|---|
| 18High | Placebo or no-added-treatment control armPD-05, evidence grade B; design risk | What does the control arm receive? Placebo or no added treatment | 3×3×2 | QTL: stopped study treatment early |
| 18High | Active comparator (against placebo) in registry dataPD-17, evidence grade B; design risk | What does the control arm receive? Placebo or no added treatment | 3×2×3 | Nothing yet |
| 18High | Fragmented, negotiated costing and contractingPOL-03, evidence grade A; country risk | United Kingdom: Costing and contracting were the longest start-up step; the national contract has shortened it · Spain: Site contracts took 117 days in 2016 and about 90 after national templates | 3×2×3 | Nothing yet |
| 18High | Ethics-committee structure (random CPP allocation, 40 Italian territorial committees, a central Polish committee, Denmark's timeliness)POL-20, evidence grade B; country risk | Poland: A central ethics committee reviews every study; its effect on timelines is not measured | 3×2×3 | Nothing yet |
| 12Medium | Comorbidity exclusionsPD-15, evidence grade B; design risk | Does the protocol exclude common comorbidities? Yes | 2×3×2 | QTL: ineligible patients randomised |
| 12Medium | Blinded placebo-controlled design instead of open-labelEB-03, evidence grade A; design risk | Is the study blinded? Blinded | 2×2×3 | Nothing yet |
| 12Medium | Blinded placebo-controlled against open designPD-06, evidence grade A; design risk | Is the study blinded? Blinded | 2×2×3 | Nothing yet |
| 12Medium | Washout periods and concomitant-medication exclusionsPD-09, evidence grade C; design risk | Is there a run-in or a washout longer than four weeks? Yes | 2×2×3 | Nothing yet |
| 12Medium | Run-in period before randomisationPD-10, evidence grade C; design risk | Is there a run-in or a washout longer than four weeks? Yes | 2×2×3 | Nothing yet |
| 12Medium | Biomarker-selected population with low marker prevalencePD-12, evidence grade B; design risk | Does entry require a biomarker, and how common is it? Yes, in more than half of patients | 2×2×3 | Nothing yet |
| 12Medium | Decentralised elementsPD-20, evidence grade C; design risk | Are any visits done remotely or at home? Some visits | 2×2×3 | Nothing yet |
| 9Medium | Mandatory audio-visual consent for all participantsRW-03, evidence grade C; country risk | India: Vulnerable participants in trials of new drugs need an audio-visual record of their consent | 3×3×1 | KRI: consent findings |
| 9Medium | Currency crisis with a fixed pharmaceutical exchange rate (Turkey 2018–2026)RW-07, evidence grade D; country risk | Turkey: A fixed pharmaceutical exchange rate has caused repeated medicine shortages | 3×3×1 | KRI: study drug at the site; QTL: stopped study treatment early |
| 6Low | Restrictive eligibility criteria and protocol complexityEB-04, evidence grade B; design risk | How many non-essential exclusions does the protocol carry? One or two | 2×3×1 | KRI: screen failure above the study's; QTL: ineligible patients randomised |
| 6Low | Eligibility criteria exclude patients (comorbidity, age, performance status, language)PB-02, evidence grade A; design risk | How many non-essential exclusions does the protocol carry? One or two · Does the protocol exclude common comorbidities? Yes | 2×3×1 | KRI: screen failure above the study's; QTL: ineligible patients randomised |
| 6Low | Restrictive eligibility criteria (organ function, brain metastases, prior or concurrent malignancy, HIV, laboratory thresholds, performance status)PD-01, evidence grade A; design risk | How many non-essential exclusions does the protocol carry? One or two | 2×3×1 | KRI: screen failure above the study's; QTL: ineligible patients randomised |
| 6Low | Number of eligibility criteria and complexity growthPD-02, evidence grade B; design risk | How many non-essential exclusions does the protocol carry? One or two | 2×3×1 | KRI: screen failure above the study's; KRI: important protocol deviations; QTL: ineligible patients randomised |
| 6Low | Racial and ethnic under-representationPB-12, evidence grade A; country risk | United States: Under-represented groups need a plan from the start; diversity action plans apply to Phase III studies | 3×2×1 | KRI: enrolment against the diversity plan |
| 6Low | The US activates its first site quickly but scales its site fleet slowlyPM-03, evidence grade B; country risk | United States: The first US site opens quickly, but the rest of the US sites open slowly | 3×2×1 | KRI: site activation overdue |
| 6Low | Start-up time for India and Turkey is unmeasuredPM-04, evidence grade C; country risk | Turkey: Start-up time has not been measured since CRO data from 2014 and 2015 · India: Start-up time is unmeasured beyond the statutory 90 working days | 3×2×1 | KRI: site activation overdue |
| 6Low | Regulator assessment backlogPOL-02, evidence grade A; country risk | United Kingdom: The regulator's backlog of 2023 was cleared, but could recur | 1×2×3 | Nothing yet |
| 6Low | Regional regulatory transition friction (EU CTR and CTIS)POL-15, evidence grade A; country risk | Spain: Applications go through the EU Clinical Trials Regulation and its portal · Poland: Applications go through the EU Clinical Trials Regulation and its portal | 3×2×1 | KRI: site activation overdue |
| 6Low | Ethics-committee re-registration or re-constitution that cuts review capacity (India 2013; Turkey 2024)RW-05, evidence grade B; country risk | Turkey: Ethics committees fell from 145 to 49 in 2024, cutting review capacity | 3×2×1 | KRI: site activation overdue |
| 6Low | Past performance as a predictorS-04, evidence grade B; design risk | Have most sites worked with the sponsor before? Yes, mostly repeat sites | 1×2×3 | Nothing yet |
| 6Low | Competing trialsS-21, evidence grade B; design risk | How many competing trials recruit the same patients? A few | 1×2×3 | Nothing yet |
| 6Low | Major earthquake in a site regionSH-11, evidence grade C; country risk | Turkey: Sites in the south-east lie in the 2023 earthquake zone | 1×2×3 | Nothing yet |
| 2Low | Site type: activation speedS-06, evidence grade A; design risk | What kind of sites will the study mostly use? A mix | 1×2×1 | KRI: site activation overdue; Study KPIs |
How the scores are worked out
- Likelihood. From the answer that switched the risk on: 3 if it cuts the recruitment rate to ×0.75 or below, 2 if it cuts it at all or changes screening or retention, 1 otherwise. From the risk's scope in the country: 3 if it touches all of the country's sites, 2 if some, 1 if only should an event recur. From the share of the study's sites whose profile carries the risk: 3 at 40% or more, 2 at 15% or more, 1 below.
- Impact. Scores 3 if the risk threatens the result, the patients' safety or their rights; 1 if it mainly adds cost; 2 for everything else, which mostly delays recruitment.
- Detectability. Scores 1 if a site-level KRI watches the risk every month, 2 if only a study-level KPI or QTL does, 3 if nothing does. A watched risk scores lower, so adding a KRI lowers the score.
- Bands. High from 18, medium from 8, out of 27.
- Method after TransCelerate RACT (2013); rules and cut-offs are epiClinical assumptions.